SCHEDULE: Centessa Pharmaceuticals: Index Ventures Confirms <5% Ownership

Index Ventures Life VI (Jersey) L.P., Yucca (Jersey) SLP, and Index Venture Life Associates VI Ltd have filed an amendment to Schedule 13G, confirming they beneficially own less than 5% of Centessa Pharmaceuticals' ordinary shares as of June 30, 2026.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership reporting for Centessa Pharmaceuticals plc.
• The reporting entities are Index Ventures Life VI (Jersey) L.P., Yucca (Jersey) SLP, and Index Venture Life Associates VI Ltd.
• As of June 30, 2026, none of these reporting persons beneficially own any ordinary shares of Centessa Pharmaceuticals.
• The aggregate amount beneficially owned by each reporting person is 0.00 shares, representing 0.0% of the class.
• The filing confirms that these entities hold 5% or less of the class of securities.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update confirming a lack of significant beneficial ownership, with no new material information impacting the company's valuation or strategic direction.

Negatives

• The filing indicates a complete divestment or a significant reduction in holdings by these Index Ventures entities, which could be interpreted negatively if they were previously significant stakeholders.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors and are used to report beneficial ownership of more than 5% of a company's voting stock. This amendment, indicating less than 5% ownership, suggests a potential shift in investment strategy or a complete exit from a significant position by these Index Ventures entities.

Stakeholder Impact

• Shareholders: The lack of significant ownership by these entities may reduce potential influence on corporate strategy, but also removes any potential for concentrated selling pressure from these specific holders.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Centessa Pharmaceuticals, Index Ventures, Ordinary Shares, Ownership Filing